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Abstract 
Purpose: To evaluate the activity of extracts of Sanghuangporus sp.1 fungus against pathogenic 
bacteria and a breast cancer cell line. 
Methods: The wild fruiting body and mycelium of Sanghuangporus sp.1 were extracted with water and 
ethanol by ultrasonication extraction. The activity of the extracts against pathogenic bacteria was 
determined by agar-well diffusion method while minimum inhibitory concentration (MIC) and minimum 
bactericidal concentration (MBC) were obtained by agar-well diffusion and broth macrodilution methods. 
The cytotoxicity of the extract against human breast cancer cell line MCF-7 was determined by 
sulforhodamine B assay. 
Results: Only the ethanol mycelial extract exhibited antibacterial activity. Activity was detected against 
6 of the 17 test strains of bacterial pathogen. The MICs and MBCs against these 6 strains were quite 
low, especially for B. cereus ATCC 11778 (2.5 and 2.5 mg/mL) and S. aureus (MSSA, DMST 2933, 2.5 
and 5.0 mg/mL). The ethanol mycelial extract was a more potently cytotoxic against MCF-7 cells than 
either the aqueous mycelial extract or the ethanol wild fruiting body extract, inhibiting cell growth at a 
concentration of 250 μg/mL. The aqueous wild fruiting body extract was inactive against MCF-7 cells 
when compared with untreated control groups. 
Conclusion: The ethanol mycelial extract of the medicinal mushroom Sanghuangporus sp.1, obtained 
by ultrasonication extraction method, exhibited potent antibacterial and anticancer activity and seems to 
be a substitute for wild Sanghuangporus sp.  
 
Keywords: Antibacterial activity, Anticancer activity, Sanghuangporus sp.1, Mycelial 
 
Tropical Journal  of Pharmaceutical Research is indexed by Science Citation Index (SciSearch), Scopus, 
International Pharmaceutical Abstract, Chemical Abstracts, Embase, Index Copernicus, EBSCO, African 
Index Medicus, JournalSeek, Journal Citation Reports/Science Edition, Directory of Open Access Journals 




Mushrooms have been used as traditional 
remedies for many years [1], playing an 
important role in traditional medicine in Japan, 
China, Korea and other Asian countries [2]. The 
bioactivity of medicinal mushrooms is due to 
constituents such as polysaccharides, 
glycoproteins, proteoglycans, fatty acids and 
proteins [3]. Macrofungi in the genus Phellinus, 
especially Phellinus linteus, are reported to have 
many potentially salutary effects including 
immunomodulatory, anti-tumor, anti-oxidant, anti-
inflammatory and antimicrobial activities [4-10].  
For example, acidic polysaccharides isolated 
from P. linteus induce the functional maturation 
of dendritic cells [11], and inotilone has in vitro 
and in vivo anti-inflammatory activities that might 
be related to increased catalase, superoxide 
dismutase and glutathione peroxidase activity [7]. 
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Hur et al [4] found that methanol extract from P. 
linteus inhibits the growth of methicillin-resistant 
Staphylococcus aureus (MRSA). 
 
Another medicinal mushroom in this genus is P. 
igniarius. Song et al [12] have demonstrated that 
P. igniarius extracts inhibit the proliferation of 
human hepatocarcinoma SK-Hep-1 cell lines in a 
dose-dependent manner. A polyphenol extract 
from P. igniarius has been reported to protect 
against acrolein toxicity in vitro, and against 
stroke in a mouse model [13]. Chang et al. [14] 
and Ayala-Zavala et al. [6] found that extracts 
from P. merrillii, P. gilvus, P. rimosus and P. 
badius have antioxidant activity. Moreover, the 
extracts from P. gilvus, P. rimosus and P. badius 
could inhibit growth of the fungus Alternaria 
alternata [6]. Extracts from P. baumii have 
activity against influenza and methicillin-resistant 
S. aureus [15,16]. These findings indicate that 
many fungi in the genus Phellinus produce 
bioactive compounds, and represent a potential 
source of new therapeutic agents. Some of the 
above species have recently been reclassified, 
including P. linteus, which has been moved from 
the Phellinus genus to the Sanghuangporus 
genus, and is now known as Sanghuangporus 
linteus.    
 
Many macrofungi in the genera Phellinus and 
Sanghuangporus have been found in the 
northeast of Thailand, but limited information is 
available on their bioactive compounds.  Only 3 
species, P. igniarius, P. gilvus and P. merrillii, 
have been reported to have antibacterial activity. 
Activity was detected against the pathogenic 
bacteria Escherichia coli, Pseudomonas 
aeruginosa and S. aureus, [17-19]. Other 
Sanghuangporus and Phellinus species merit 
investigation as source of new products that 
could be developed as novel therapeutic agents 
in the future. Therefore, the aim of the present 
study was to isolate the medicinal 
Sanghuangporus fungus from the wild fruiting 
body and then evaluate the activity of different 
extracts against Gram-negative and Gram-
positive pathogenic bacteria by the agar well and 
macro-dilution method.  The effect of these 





Fungal isolation  
 
The wild fruiting body of the medicinal mushroom 
used in this study was provided by the Natural 
Medicinal Mushroom Museum, Mahasarakham 
University, Thailand (J. Naksuwankul 720 
(MSUT)) (Figure 1). The Sanghuangporus sp.1 
fungus fruiting bodies were washed several times 
with sterile distilled water and then the inner 
tissue of the fruiting bodies was cut into small 
pieces (5 x 5 mm2) before being surface 
sterilized and transferred to potato dextrose agar 
(PDA) containing 100 mg/mL ampicillin. After 7 
days, the white mycelium growing out of the 
fungal tissue was sub-cultured on potato 
dextrose agar (PDA) and incubated at 25 - 28 oC. 
 
Preparation of extracts  
 
Mycelial discs of the Sanghuangporus sp.1 
fungus were cut with a sterile cork borer and 
placed into 25 mL of PDB medium.  The culture 
was incubated statically at 28 °C for 20 days. 
The mycelium on the surface of the culture was 
collected and dried at 50 °C for 2 - 3 days before 
being powdered using a mortar and pestle. Five 
hundred milligram aliquots of the dried mycelium 
were placed in conical screw cap tubes and 
dissolved in either 12.5 mL of distilled water or 
50 % ethanol.  The mycelium suspension (40 
mg/mL) was then sonicated using the 
ultrasonication extraction method described by 
Sangdee and Sangdee [20]. The dried wild 
fruiting body was cut into small pieces before 
being powdered using a mortar and pestle. 
Aqueous and ethanol extraction of the wild 
fruiting body was performed as described above. 
 
Test bacteria  
 
All the extracts were screened for activity against 
15 reference strains of bacteria (Bacillus cereus 
ATCC 11778, Escherichia coli [EIEC] DMST 
30545, E. coli O157:H7 DMST 12743, , 
Salmonella enterica serovar Typhimurium ATCC 
14028, S. enterica serovar Typhi DMST 22842, 
S. enterica serovar Typhi DMST 16122, Shigella 
flexneri DMST 4423, Sh. flexneri DMST 17569, 
Sh. dysenteriae DMST 15110, Staphylococcus 
aureus [MSSA] DMST 2933, S. aureus [MRSA] 
DMST 4738, S. aureus [MRSA] DMST 20651, S. 
aureus [MRSA] DMST 20654, Pseudomonas 
aeruginosa ATCC 27853 and Vibrio cholerae 
[O1] DMST 9700).  The 12 DMST reference 
strains were obtained from the Culture Collection 
for Medical Microorganisms, Department of 
Medical Sciences, Thailand. Two clinical isolates 
were also tested (Klebsiella pneumoniae and 
Pseudomonas aeruginosa). 
 
Primary screening for antibacterial activity 
 
The antibacterial activity of the extracts was 
initially screened using an agar well diffusion 
method. The screening method was performed 
as described by Sangdee et al [21].  Briefly, the 
15 test bacteria were cultured by inoculating a 
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single bacterial colony into Mueller Hinton broth 
(MHB), and then incubating with shaking (150 
rpm) at 37 °C for 3 h.  The cultures were then 
adjusted to the turbidity of a 0.5 McFarland 
standard. These cell suspensions were 
inoculated and spread over the entire surface of 
each Mueller Hinton agar (MHA) plate, and the 
agar plates were then cut using a sterile cork 
borer. Finally, 0.1 mL of 40 mg/mL of the extracts 
was added to each well (4 mg per well). After 
incubation at 37 °C for 16 – 18 h, the zones of 
inhibition in each plate were measured. Cipro-
floxacin at a concentration of 250 g/mL was 
used as a reference standard. 
 
Minimum inhibitory concentration (MIC) and 
minimum bactericidal concentration (MBC) 
assays 
 
For extracts that showed a detectable zone of 
inhibition against the test bacteria, this activity 
was quantified by MIC and MBC assay. The 
MICs of the extracts were determined using the 
agar well diffusion method and broth 
macrodilution method. The agar well diffusion 
method was performed as described above, but 
testing a series of concentrations (40, 20, 10, 5, 
2.5 and 1.25 mg/mL). The MIC represented the 
lowest concentration of extract capable of 
inhibiting bacterial growth around the well. The 
broth macrodilution method involved preparing a 
series of concentrations of extract (40, 20, 10, 5, 
2.5 and 1.25 mg/mL) in MHB medium, then 
inoculating each with 0.1 mL of bacterial 
suspension. The final cell density of bacteria was 
105 CFU/mL. The mixtures were incubated with 
shaking for 24 h (150 rpm). MICs were 
determined by identifying the solutions that were 
clear after incubation compared with the control 
tubes (MHB plus test bacteria, MHB plus the 
extracts, and MHB plus antibiotic and test 
bacteria). MBCs were determined by transferring 
bacterial suspensions from the MIC assay onto 
MHA plates. The lowest concentration that 
resulted in no growth after 24 h incubation was 
recorded as the MBC. Ciprofloxacin and 
tetracycline, each at a concentration of 250 
g/mL were used as reference standards. Two 
strains of methicillin-resistant Staphylococcus 
aureus (MRSA), viz, S. aureus DMST 4738 and 
S. aureus DMST 20654 at final cell density of 105 
CFU/mL were used as test bacteria in the study. 
 
Evaluation of cytotoxicity against human 
breast cancer cells 
 
The effects of the extracts on the human breast 
cancer cell line MCF-7 were determined as 
described by Buranrat et al [22] using the 
sulforhodamine B (SRB) assay. Briefly, MCF-7 
cells were seeded into a 96-well plate (1x104 
cells/well) for 24 h before being exposed to the 
extracts at various concentrations for 72 h. After 
that, the cultured medium was removed, fixed 
with ice-cold methanol, stained with 0.4 % SRB, 
and solubilized with 10 mM Tris-base buffer. The 
absorbance was measured at 540 nm using a 





Fungal isolation and colony morphology 
 
Within 7 - 10 days, the mycelium of the fungus 
Sanghuangporus sp.1 grew out of the tissue of 
the wild fruiting body and formed white colonies 
on PDA. The mycelium was sub-cultured onto a 
new PDA plate for morphological examination. 
After 3 - 5 days, the color of the colonies was 
white, these then changing to white-cream 
cottony colonies by 10 - 14 days.  The colonies 
grew quickly, covering the surface of the 90 mm 
PDA plate by 21 days (Figure 1).  This isolate 
was assigned the reference number 
Sanghuangporus sp.1. 
 
Antibacterial activity of mycelial and fruiting 
body extracts 
 
In this study, mycelial extracts and wild fruiting 
body extracts of Sanghuangporus sp.1 were 
tested against 15 strains of pathogenic bacteria 
using an agar well diffusion method. The results 
showed that only the ethanolic mycelial extract 
exhibited antibacterial activity. Activity was 
detected against 4 of the 15 test bacterial strains 
including S. aureus [MSSA] DMST 2933, S. 
aureus [MRSA] DMST 20651, B. cereus ATCC 
11778 and Vibrio cholerae [O1] DMST 9700. The 
aqueous mycelial extract, aqueous wild fruiting 
body extract, and ethanolic wild fruiting body 
extract had no effect against the test bacteria. 
The inhibition zones of the ethanolic mycelial 
extract ranged from 11 - 24 mm, whereas the 
inhibition zones of the antibiotic ciprofloxacin 
ranged from 15 - 34 mm.  Interestingly, 3 of the 
test bacteria, B. cereus ATCC 11778, S. aureus 
[MSSA] DMST 2933 and S. aureus [MRSA] 
DMST 20651, were more sensitive to the 
ethanolic extract than to ciprofloxacin. Moreover, 
S. aureus (MRSA) DMST 20651 was sensitive to 
the ethanolic mycelial extract, but resistant to 
ciprofloxacin (Table 1). 
 
The MIC and MBC values of the ethanolic 
mycelial extract were determined against the 
sensitive strains above and against two strains of 
methicillin-resistant Staphylococcus aureus, 
strains DMST 4738 and DMST 20654. 
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Figure 1: Basidiocarp (A and B) and a colony of the medicinal mushroom Sanghuangporus sp.1 on PDA medium 
at 7, 14 and 22 days (C, D and E). (J. Naksuwankul 720 (MSUT) 
 
Table 1: Primary antibacterial screening of the aqueous mycelial extract, ethanolic mycelial extract, aqueous 
fruiting body extract, and ethanolic fruiting body extract of Sanghuangporus sp.1 using the antibiotic ciprofloxacin 
as a reference standard 
 
Test bacterium 
Zone of inhibition (mm) 
Mycelial extract Fruiting body extract  Cipro (25 g) 
Aqueous EtOH Aqueous EtOH 
B. cereus ATCC 11778 0 23x23 0 0 15x15 
S. aureus (MSSA) DMST 2933 0 20x20 0 0 17x17 
S. aureus (MRSA) DMST 4738 ND ND ND ND ND 
S. aureus (MRSA) DMST 20651 0 24x24 0 0 0 
S. aureus (MRSA) DMST 20654 ND ND ND ND ND 
V. cholerae (O1) DMST 9700 0 11x11 0 0 34x34 
E. coli (EIEC) DMST 30545 0 0 0 0 13x13 
E. coli O157:H7 DMST 12743 0 0 0 0 25x25 
Sh. flexneri DMST 4423 0 0 0 0 26x26 
Sh. flexneri DMST 17569 0 0 0 0 29x29 
S. Typhi DMST 22842 0 0 0 0 30x30 
S. Typhi DMST 16122 0 0 0 0 25x25 
Sh. dysenteriae DMST 15110 0 0 0 0 30x30 
S. Typhimurium ATCC 14028 0 0 0 0 26x26 
Ps. aeruginosa ATCC 27853 0 0 0 0 27x27 
Ps. aeruginosa 0 0 0 0 18x18 
K. pneumonia 0 0 0 0 23x23 
EtOH, ethanol; Cipro, ciprofloxacin; ND, not determined; MIC, minimum inhibitory concentration; MBC, minimum 
bactericidal concentration 
 
The MICs of the ethanolic mycelial extract were quite low ranging from 2.5-10 mg/mL by the agar well 
diffusion method.  The MIC values of the same extract measured by the broth macrodilution method 
were 2.5-5 mg/mL.  B. cereus ATCC 11778 and S. aureus [MSSA] DMST 2933 were the most 
sensitive. The MBC values of the ethanolic mycelial extract ranged from 2.5-5.0 mg/mL, with B. 
cereus ATCC 11778 being the most sensitive (Table 2). 
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Table 2: MIC and MBC values of the ethanolic mycelial extract of Sanghuangporus sp.1 against 6 strains of 
pathogenic bacteria 
 
Test bacterium MIC (mg/mL) MBC (mg/mL) 
Agar well method Broth macrodilution 
method 
B. cereus ATCC 11778 2.5 2.5 2.5 
S. aureus (MSSA) DMST 2933 2.5 2.5 5.0 
S. aureus (MRSA) DMST 20651 10.0 5.0 5.0 
S. aureus (MRSA) DMST 4738 5.0 5.0 5.0 
S. aureus (MRSA) DMST 20654 10.0 5.0 5.0 
V. cholerae (O1) DMST 9700 10.0 5.0 5.0 
 
Cytotoxicity against human breast cancer 
cells 
 
The cytotoxicity of the extracts against MCF-7 
cells was evaluated using the SRB assay. The 
results showed that MCF-7 cells were more 
sensitive to the mycelial extracts than the wild 
fruiting body extracts. The ethanolic mycelial 
extract had greater cytotoxicity against the MCF-
7 cells than either the aqueous mycelial extract 
or the ethanolic wild fruiting body extract. No 
activity was detected from the aqueous wild 
fruiting body extract against the MCF-7 cells. At 
72 h, the aqueous and ethanolic mycelial 
extracts at concentrations of 500 μg/mL and 250 
μg/mL inhibited MCF-7 cell growth when 
compared to untreated cells (Figure 2). 
Moreover, the results showed that cell growth 
was strongly inhibited by ethanolic mycelial 
extracts in a dose-dependent manner with an 
IC50 value of 1122.67 ± 203.09 μg/mL, while no 
activity was detected from the aqueous wild 




Figure 2:  Effect of the aqueous mycelial extract (A), ethanol mycelial extract (B), aqueous wild fruiting body 
extract (C) and ethanol fruiting body extract (D) of Sanghuangporus sp.1 on the growth of MCF-7 cells.  The cells 
were cultured for 24 h in 96-well plates and then treated with various concentrations of the extracts for 72 h 
before cell viability was determined by the SRB assay. The bars show mean ± SEM, each from three 
independent experiments; *p < 0.05 vs. untreated control groups 
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In recent years, it has been proposed that 
several mushrooms belonging to the genera 
Sanghuangporus, Phellinus and Inonotus, such 
as S. linteus, Inonotus obliquus, I. xeranticus and 
P. ignarius could be used as nutritionally 
functional foods or as sources of medicinally 
useful compounds [23]. Examples of bioactive 
constituents include polysaccharides, especially 
β-glucan, which enhances immune system 
activity [24]. They also produce compounds with 
antioxidant activity [25,26]. In the present study, 
Sanghuangporus sp.1 was isolated and 
screened for antibacterial and anticancer 
activities.  
 
The activity of artificially cultivated 
Sanghuangporus sp.1 extracts were compared 
with those of the wild fruiting body. The results 
indicate that the ethanolic mycelial extract has 
superior activity against S. aureus [MSSA] DMST 
2933, S. aureus [MRSA] DMST 20651, S. aureus 
[MRSA] DMST 4738, S. aureus [MRSA] DMST 
20654, B. cereus ATCC 11778 and Vibrio 
cholerae [O1] DMST 9700 than extracts from the 
wild fruiting body.  Interestingly, the ethanolic 
mycelial extract had activity against the medically 
important pathogenic bacteria S. aureus [MSSA] 
DMST 2933, S. aureus (MRSA) DMST 20651 
and S. aureus (MRSA) DMST 20654, the latter 2 
strains being resistant to ciprofloxacin. These 
results correlate well with those of Hur et al [4], 
who demonstrated that extracts from S. linteus 
have good activity against methicillin-resistant 
Staphylococcus aureus.  
 
Similar findings to those above were observed in 
the cytotoxicity assay, with both mycelial extracts 
having greater cytotoxicity against the MCF-7 
breast cancer cell line than the wild fruiting body 
extracts. These results indicate that mycelia 
cultivated in the laboratory are more bioactive, 
and may produce more potent medicinal 
compounds. These results correlate well with 
those of Sun et al [27], who demonstrated that 
artificially cultivated I. obliquus have similar 
inhibitory activity against tumor cells and 
bioactive compounds as wild I. obliquus.  Our 
findings also suggest that the bioactivity of the 
ethanolic mycelial extract of Sanghuangporus 
sp.1 is significantly greater than the other 
extracts.  
 
This comparative study indicates that the 
medicinal mushroom Sanghuangporus sp.1 can 
be grown in the laboratory and used as a source 
of broad-spectrum antibacterial and anticancer 
agents.  It can therefore be considered an 
alternative to wild Sanghuangporus spp. 
However, further studies will be required to 
isolate and identify the compounds responsible 
for the anticancer properties of the extracts and 
elucidate the mechanism of action of ethanolic 
mycelial extract against breast and other cancer 
cells.   
 
Finally, the extraction procedure is important for 
isolating active components from many 
organisms including plants [28] and fungi [29]. In 
this study, we used the ultrasonication method to 
isolate bioactive compounds from both fungal 
mycelia and the fruiting body. The results 
indicate that this method does extract 
compounds with antibacterial and anticancer 
activity. However, other parameters including the 
type of solvent should be considered, because 
different solvents have different polarities, and 
therefore extract compounds of different 
polarities. For example, the ethanolic mycelial 
extract showed more antibacterial and anti-
breast cancer cell line activity than those of the 
aqueous mycelial extract. These observations 
may be due to different bioactive compounds 
being extracted or different quantities of bioactive 
compound being extracted. Suitable extraction 
methods and extraction parameters should 
therefore be identified before large scale 





This study shows that extracts of the medicinal 
mushroom Sanghuangporus sp.1 exhibit 
significant in vitro antibacterial and anticancer 
activities. Furthermore, the extracts of laboratory-
grown Sanghuangporus sp.1 mycelia are at least 
as active as those of the wild fruiting body of 
Sanghuangporus sp.1, and can therefore be 
used as a source of bioactive agents. Further 
studies are, however, required to isolate and 
identify the compounds responsible for the 
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